CASE PRESENTATION {#s1}
=================

A 41-year-old man with severe alcohol use disorder was admitted to a hospital in Alabama in January with 2 days of productive cough, shortness of breath, and fever. He presented with septic shock, hypoxemic respiratory failure, and bilateral pulmonary infiltrates ([Figure 1](#F1){ref-type="fig"}). Laboratory results were notable for neutropenia (absolute neutrophil count 450 cells/mcL), thrombocytopenia (58 000 cells/mcL), and acute kidney injury (creatinine 1.9 mg/dl). He had a history of alcohol use disorder with prior alcohol withdrawal seizures. His level of recent alcohol consumption was unknown, but he did not have evidence of alcohol withdrawal during the hospitalization. He lived with his father in rural Alabama and was unemployed. He smoked approximately 5 cigarettes per day and did not use illicit drugs. He had no travel outside the eastern United States, no recent health care exposures, and no sick contacts.

![Anterior--posterior chest x-ray showing bilateral infiltrates consistent with multifocal pneumonia.](ofy04401){#F1}

He was started on vancomycin, piperacillin-tazobactam, levofloxacin, and oseltamivir. Hypoxemia progressed rapidly, and within the first 24 hours of hospitalization he was intubated with high ventilatory support requirements (FiO~2~ of 100% and positive-end expiratory pressure of 18 cm of water) despite paralysis with cisatracurium. Blood cultures from admission grew Gram-negative bacilli in both sets in the aerobic bottles after 12 hours of incubation. The organism was identified as *Acinetobacter baumannii* by matrix-assisted laser desorption ionization time of flight mass spectroscopy (MALDI-TOF). Drug resistance testing, performed by an automated biochemical testing system (MicroScan Walkaway, Beckman Coulter, Inc. Brea, CA), showed sensitivity to all antimicrobials tested, including ceftazidime, levofloxacin, ampicillin-sulbactam, and meropenem.

The patient was transferred to our institution for initiation of venovenous extracorporeal membrane oxygenation (ECMO). On arrival, he required norepinephrine and vasopressin for blood pressure support, and antimicrobials were changed to intravenous meropenem and levofloxacin. Bronchoalveolar lavage showed many Gram-negative coccobacilli on Gram stain with growth of *A. baumannii* in culture with similar sensitivity to the previously obtained blood cultures. Antimicrobials were changed to intravenous ampicillin-sulbactam and levofloxacin, and he completed a 14-day course of therapy. His ECMO was discontinued after 9 days of therapy. He continued to require ventilatory support, necessitating tracheostomy, and was transferred to a subacute rehabilitation facility with eventual recovery.

DISCUSSION {#s2}
==========

*Acinetobacter baumannii* is an aerobic, oxidase-negative nonfermenting Gram-negative coccobacillus most often associated with hospital-acquired infections, particularly ventilator-associated pneumonia (VAP). Hospital-acquired *A. baumannii* is associated with extended length of hospital stay and high mortality \[[@CIT0001]\]. However, during the last 25 years, there has been a growing body of literature describing severe community-acquired pneumonia due to *A. baumannii* (CAP-AB) in patients without health care exposure or classic risk factors for this organism \[[@CIT0002]\]. The majority of these cases come from Northern Australia and Asia, including Thailand, China, Taiwan, and are more common in tropical and subtropical areas during the summer months. Throat and skin carriage of *Acinetobacter* has been identified in areas of endemicity, and soil, livestock, and other animals have also been shown to serve as community reservoirs for *Acinetobacter* \[[@CIT0003]\]. Based on pulse-field gel electrophoresis analyses, community-acquired isolates represent a distinct lineage from health care--associated *Acinetobacter* infections and often do not harbor the same resistance mechanisms \[[@CIT0003]\]. Although less drug-resistant than hospital-acquired *A. baumannii* bacteremia, community-acquired infection has been associated with increased mortality (odds ratio, 5.72; 95% confidence interval, 1.02--32.00) \[[@CIT0004]\].

Epidemiologic studies have linked the syndrome of severe CAP-AB with alcohol use disorder and recent alcohol binges prior to symptom onset \[[@CIT0005]\]. Animal studies have shown that alcohol has wide-ranging effects on the innate immune system in relation to pulmonary *Acinetobacter* infection \[[@CIT0006]\]. Gandhi et al. compared ethanol-exposed mice with unexposed mice after pulmonary inoculation of *Acinetobacter* \[[@CIT0006]\]. They showed that ethanol-exposed mice demonstrated decreased neutrophil- mediated phagocytosis, increased lung inflammation, and higher mortality. Asplund et al. similarly showed decreased alveolar macrophage phagocytosis of *Acinetobacter* in the presence of alcohol \[[@CIT0007]\]. Other significant risk factors include tobacco use, chronic pulmonary disease, and diabetes mellitus \[[@CIT0002]\]. Onset of symptoms is typically rapid, with fulminant disease developing over 48--72 hours. Bilateral infiltrates, ARDS, leukopenia, and bacteremia are all common. A right-lung predominance has been noted, which likely implicates an element of aspiration to the pathogenesis of this condition \[[@CIT0009]\]. Taking into account characteristics from multiple series, a distinct clinical syndrome of CAP-AB emerges (Box 1).

###### 

BOX 1. Characteristics Of The Cap-Ab Syndrome

  ------------------------------------------------
  Rapid onset of symptoms with fulminant disease
  Alcohol use disorder, especially binge episode
  Leukopenia
  Middle-aged men
  Tobacco use
  Right \> left lung infiltrates
  Warm moist environments
  ------------------------------------------------

To date, 19 cases of CAP-AB have been reported in North America ([Table 1](#T1){ref-type="table"}). While most cases of CAP-AB in Southeast Asia and Australia have been reported since the late 1990s, most North American cases were published between 1959 and 1981, with the most recent report from 1999 \[[@CIT0010]\]. Overall, these North American cases conform to the typical presentation of the "CAP-AB syndrome" described outside of North America. Most patients were middle-aged (median age, 54 years), male (15/19), and reported a history of alcohol use (10/19). All but two patients presented with a rapid-onset of illness with ≤3 days of symptoms and fulminant disease. Eleven of 15 patients with reported information on respiratory support required mechanical ventilation. Our patient was the only case with the use of ECMO for cardiopulmonary support. Mortality was high (42%), although many of the cases occurred prior to the advent of modern diagnostic and therapeutic advances, which is exemplified by the frequent use of aminoglycosides as definitive therapy (13/19 cases).

###### 

Summary of North American Cases of Community-Acquired Pneumonia due to *Acinetobacter baumannii*

  Year (Reference)      Location           Age   Sex   Risk Factors                       Mech. Vent.   Site of Positive Cultures             Final Antibiotics Used                                  Outcome
  --------------------- ------------------ ----- ----- ---------------------------------- ------------- ------------------------------------- ------------------------------------------------------- ----------
  1959 \[[@CIT0010]\]   Chicago, IL        50    M     None                               No            Blood and sputum                      Chloramphenicol and oxytetracycline                     Survived
  1968 \[[@CIT0011]\]   Chapel Hill, NC    49    M     Alcohol                            No            Blood and lung tissue (autopsy)       Penicillin G                                            Died
  1973 \[[@CIT0012]\]   Baltimore, MD      69    M     CKD                                Yes           Tracheal aspirate and pleural fluid   Tetracycline                                            Died
  1976 \[[@CIT0013]\]   Houston, TX        50    M     Alcohol, tobacco                   Yes           Blood and tracheal aspirate           Gentamicin and carbenicillin                            Survived
  1977 \[[@CIT0014]\]   Philadelphia, PA   33    F     Alcohol, tobacco                   No            Sputum                                Gentamicin and cephalothin                              Died
                                           58    M     Alcohol, cirrhosis, tobacco        Yes           Sputum                                Gentamicin                                              Survived
  1979 \[[@CIT0015]\]   Dallas, TX         58    M     Alcohol, asthma                    ?             Blood                                 Clindamycin and gentamicin                              Died
                                           41    M     Alcohol, pancreatitis, hepatitis   Yes           Blood and tracheal aspirate           Penicillin, gentamicin, and carbenicillin               Survived
                                           35    F     Alcohol                            Yes           Blood and tracheal aspirate           Penicillin and gentamicin                               Died
                                           51    M     Lymphoma                           ?             Blood and sputum                      Gentamicin and carbenicillin                            Survived
                                           74    F     None                               ?             Blood and sputum                      Penicillin and gentamicin                               Survived
                                           44    M     Alcohol, chronic bronchitis        ?             Blood and sputum                      Penicillin, gentamicin, and carbenicillin               Survived
  1981 \[[@CIT0016]\]   Hartford, CT       54    M     Pneumoconiosis                     Yes           Blood and sputum                      Penicillin G                                            Died
                                           63    M     Alcohol, tobacco                   Yes           Blood and sputum                      Gentamicin and carbenicillin                            Survived
                                           56    M     Pneumoconiosis                     Yes           Blood and sputum                      Ticarcillin and tobramycin                              Died
  1987 \[[@CIT0017]\]   San Antonio, TX    56    M     Tobacco                            Yes           Sputum                                Gentamicin and clindamycin                              Died
  1993 \[[@CIT0018]\]   Chicago, IL        74    F     None                               Yes           Blood                                 Gentamicin, ticarcillin-clavulanate, and erythromycin   Survived
  1999 \[[@CIT0019]\]   Tampa, FL          80    M     None                               No            BAL                                   Trimethoprim- sulfamethoxazole                          Survived
  2017                  Atlanta, GA        41    M     Alcohol                            Yes           Blood and BAL                         Ampicillin-sulbactam and levofloxacin                   Survived

Abbreviations: ?, unreported data; BAL, bronchoalveolar lavage; CKD, chronic kidney disease; F, female; M, male.

It is possible that CAP-AB in North America occurs more frequently but is underreported because identification of *Acinetobacter* is not noteworthy outside of the community-acquired context. It is also possible that climate plays a role in identification of only a small number of cases in the northern hemisphere, as the majority of cases have been identified in tropical locations \[[@CIT0002]\]. Studies have demonstrated that even health care--associated cases may have some seasonal variation. For example, when surveillance data on *Acinetobacter* infections were collected at Yale--New Haven Hospital from 1990--1992, the incidence during the summer months was more than double the incidence during the remainder of the year \[[@CIT0020]\]. The fact that our patient became critically ill during the winter is therefore unusual, although multiple cities in Alabama documented record high average temperatures throughout the year of this patient's illness \[[@CIT0021]\]. The etiology of this association of cases with warmer temperatures remains unknown and is a potential area for further study, especially as it suggests that climate change could ultimately influence disease prevalence.

CONCLUSION {#s3}
==========

This case is a representative example of the CAP-AB syndrome in a patient in the Southeast United States in 2017. While much focus is appropriately directed toward multidrug-resistant nosocomial *Acinetobacter* infections, we present this case to raise awareness of the presence of CAP-AB and document its contemporary existence outside of its typical area of endemicity. Previous reported cases in North America have been sporadic and infrequent since the 1950s, but globalization, climate change, and increasing prevalence of alcohol use disorder \[[@CIT0022]\] could lead to emergence of this syndrome in the United States.

***Financial support.*** This work is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR002378 and TL1TR002382, both D.P.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

***Potential conflicts of interest.*** All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
